Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03190772
Other study ID # 2017-12k
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 1, 2017
Est. completion date September 30, 2018

Study information

Verified date November 2018
Source Philipps University Marburg Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study aimes at identifying whether positive expectations have an impact on the way depressive participants experience emotions in the form of sadness.


Recruitment information / eligibility

Status Completed
Enrollment 94
Est. completion date September 30, 2018
Est. primary completion date September 30, 2018
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- major depression (mild to moderate)

- fluent in German language

Exclusion Criteria:

- bipolar disorder, psychotic disorder, substance dependence

- cardiovascular disease, severe kidney or liver disease, epilepsy

- change of psychotropic medication intake within the last four weeks

- allergic to capsaicin

- allergic to sesame oil

- students in medicine, pharmacy, or psychology in their third year or older

- completed studies in medicine, pharmacy or psychology

Study Design


Intervention

Other:
Placebo nasal spray
The placebo nasal spray consists of sesame oil and does not contain any active drug.
Film sequence
All groups watch the film sequence that is supposed to induce sadness.

Locations

Country Name City State
Germany Justus Liebig University Gießen Gießen Hessen
Germany Philipps University Marburg Marburg Hessen

Sponsors (1)

Lead Sponsor Collaborator
Philipps University Marburg Medical Center

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sadness Items of PANAS-X Directly after watching the film sequence, no follow-up assessments
See also
  Status Clinical Trial Phase
Completed NCT03256162 - Ketamine as an Adjunctive Therapy for Major Depression Phase 1
Completed NCT01944293 - Ketamine for Suicidality in Bipolar Depression Phase 1/Phase 2
Recruiting NCT01441505 - A Study of Ketamine as an Antidepressant Phase 2
Active, not recruiting NCT03487926 - Microglial Activation in Inflammatory Bowel Disease
Recruiting NCT04939649 - Ketamine as an Adjunctive Therapy for Major Depression (2) Phase 3
Recruiting NCT05028738 - Patient-oriented Randomized Pragmatic Feasibility Trial With rTMS in Depression and Anxiety N/A
Recruiting NCT03646058 - Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode Phase 3
Not yet recruiting NCT06117397 - A Text Messaging Intervention to Reduce Perinatal Depression Risk N/A
Completed NCT03735576 - Cognitive Behavioural Therapy for the Treatment of Late Life Depression N/A
Recruiting NCT04999553 - Left vs. Right Non-Inferiority Trial N/A
Completed NCT03716869 - Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder N/A
Recruiting NCT02824081 - Neuroinflammation, Serotonin, Impulsivity and Suicide N/A
Terminated NCT01099592 - Antidepressants to Promote Recovery of Cardiac Patients Suffering From Depression Phase 4
Completed NCT03752853 - Stress Systems and Psychotherapy in Depression N/A
Recruiting NCT04480918 - University of Iowa Interventional Psychiatry Service Patient Registry
Recruiting NCT04130958 - Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics N/A
Recruiting NCT04832750 - Depression-Reduction by Accelerated Personalized NeuroModulation and Its Effects on Sleep
Terminated NCT02839798 - NeoSync TMS Treatment for Bipolar I Depression Phase 2
Completed NCT00852592 - Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial Phase 3
Terminated NCT05063604 - Antidepressant Efficacy of Psychotherapy and Citalopram in Patients With Breast Cancer and Major Depression Phase 2